1. Home
  2. ADXN vs JAGX Comparison

ADXN vs JAGX Comparison

Compare ADXN & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addex Therapeutics Ltd

ADXN

Addex Therapeutics Ltd

N/A

Current Price

$2.93

Market Cap

5.1M

Sector

Health Care

ML Signal

N/A

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.02

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADXN
JAGX
Founded
2002
2013
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
4.4M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
ADXN
JAGX
Price
$2.93
$2.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.6K
★ 1.9M
Earning Date
11-09-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.42
EPS
★ N/A
N/A
Revenue
N/A
★ $11,511,000.00
Revenue This Year
$767.75
$77.78
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.56
$0.20
52 Week High
$10.43
$41.53

Technical Indicators

Market Signals
Indicator
ADXN
JAGX
Relative Strength Index (RSI) 44.07 44.65
Support Level $2.60 $0.39
Resistance Level $3.25 $3.07
Average True Range (ATR) 0.19 0.41
MACD 0.04 -0.27
Stochastic Oscillator 47.48 0.71

Price Performance

Historical Comparison
ADXN
JAGX

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: